Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Aug 14;5(4):36.
doi: 10.1186/alzrt195. eCollection 2013.

Amyloid imaging in clinical trials

Rik Ossenkoppele  1 , Niels D Prins  2 , Bart Nm van Berckel  3
Affiliations

Amyloid imaging in clinical trials

Rik Ossenkoppele et al. Alzheimers Res Ther. .

Abstract

The possibility to map amyloid-beta, the Alzheimer's disease hallmark protein, in vivo opens the application for amyloid imaging in clinical trials with disease-modifying agents. Monitoring change in amyloid burden, particularly when potential amyloid-lowering drugs are at play, requires accurate analytical methods. Studies to date have used suboptimal methods that do not account for heterogeneous changes in flow associated with disease progression and potentially with anti-amyloid drugs. In this commentary, we discuss practical and methodological issues regarding longitudinal amyloid imaging and propose several quantitative, yet feasible, alternatives for reliable assessment of changes over time in amyloid burden.

PubMed Disclaimer

References

    1. Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, de Llano SR M, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;5:363–372. doi: 10.1016/S1474-4422(10)70043-0. - DOI - PubMed
    1. Farlow M, Arnold SE, van Dyck CH, Aisen PS, Snider J, Porsteinsson AP, Friedrich S, Dean RA, Gonzales C, Sethuraman G, DeMattos RB, Mohs R, Paul SM, Siemers ER. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement. 2012;5:261–271. doi: 10.1016/j.jalz.2011.09.224. - DOI - PubMed
    1. Sperling RA, Salloway S, Raskind M, Ferris S, Liu E, Yuen E, Lu Y, Wang D, Nejadnik B, Guenzler V, Grundman M, Black R, Brashear R, In 16th Congress of the European Federation of Neurological Societies; September 8–11 2012. Bapineuzumab Study 302 Investigators: A randomized, double-blind, placebo-controlled clinical trial of intravenous bapineuzumab in patients with mild to moderate Alzheimer's disease who are apolipoprotein E e4 carriers. European Federation of Neurological Societies: Stockholm; 2012.
    1. Wu Y, Carson R. Noise reduction in the simplified reference tissue model for neuroreceptor functional imaging. J Cereb Blood Flow Metab. 2002;5:1440–1452. - PubMed
    1. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;5:834–840. - PubMed

LinkOut - more resources